Ofatumumab for Multiple Sclerosis Does Not Increase COVID-19 Severity
Presenting at CMSC 2022, researchers evaluated COVID-19 outcomes among patients with MS who received treatment with ofatumumab.
Presenting at CMSC 2022, researchers evaluated COVID-19 outcomes among patients with MS who received treatment with ofatumumab.
Researchers sought to determine whether patients who discontinued treatment with ponesimod had an increased risk for MS disease activity exacerbation.
Presenting at CMSC 2022, researchers evaluated the response to the mRNA-1273 vaccine in patients who received DMTs for MS.
Presenting at CMSC 2022, researchers evaluated whether racial patterns exist in NMOSD- and MOGAD-associated ON and the potential role of social disadvantage in these patterns.
Presenting at CMSC 2022, researchers observed how ECG patterns relate to different demographic, clinical, and patient-specific characteristics in patients with MS.
Presenting at CMSC 2022, researchers obtained real-world data on the efficacy and safety of oral cladribine in patients with relapsing-remitting multiple sclerosis.
In a quantitative study, researchers assessed the efficacy of TMS on depressive symptoms in people with MS.
Presenting at CMSC 2022, researchers evaluated the prognostic value of baseline NfL for predicting clinical relapse and change in MRI lesion activity among patients with MS.
Presenting at CMSC 2022, researchers analyzed the development of whole-brain atrophy and white matter lesions in patients with CDMS.
Presenting at CMSC 2022, researchers evaluated the decline in the anti-JCV antibody index in patients with MS through 2 years of ocrelizumab treatment.